MRX · Marex Group plc

Current Thesis

The roll-up compounder thesis is now confirmed by hard numbers rather than expectation. Q1 2026 (reported 2026-05-06) was a record: revenue $692.3M, +48% YoY (Q1'25 $467.3M), reported PBT $149.8M (+$51.8M, 21.6% margin), adjusted PBT +59% to $153M, driven by elevated commodity volatility lifting Market Making and Hedging & Investment Solutions. The 2026-06-01 Levmet bolt-on extends a five-deal-in-twelve-months cadence. The catch: price has already discounted most of it +39.9% over 90 days to ~$55.89, sitting just under the 52-week high ($58.62) and at the $57.43 consensus PT. The cheap re-rating from the mid-$40s is spent; the open question is whether the compounder keeps grinding as estimates climb.

Bull Case

• Record Q1 prints the compounder thesis (2026-05-06): revenue +48% YoY and adjusted PBT +59% is operating leverage on a volatility tailwind, with margin expanding to 21.6% from 21.0%. Clearing balances rose to $16bn on client wins and larger margin requirements.
• Levmet bolt-on (2026-06-01) deploys the $500M senior-notes dry powder priced 2026-04-17. Monaco-based liquidity provider across base/ferrous metals, energy and power; adds European power and gas market-making diversifying earnings mix away from pure clearing.
• M&A flywheel is accelerating: Hamilton Court (FX, 2025-07-01) → Winterflood (UK equity MM, 2025-07-25) → Valcourt (fixed income MM, 2025-10-22) → Webb Traders (equity derivatives MM, 2026-02-06) → Levmet (2026-06-01). Cadence has tightened to roughly one deal per quarter, each positioned as accretive.
• Capital-return signal: Q1 dividend raised to $0.16/share, and the 2026-05-21 AGM approved a 10% buyback authority management signalling it views the share count as cheap at ~11.6x earnings.
• Valuation still undemanding: P/E 11.58 on a business compounding PBT ~50%+. A compounder at low-double-digit earnings can keep working on rising estimates even without multiple expansion.
• Sell-side confirming, not topping: UBS PT raised to $60 from $56; consensus "Strong Buy", avg PT $57.43, KBW Outperform standing (reinstated 2026-04-08). Upgrades are following the move higher.

Bear Case

• Price has caught the story: at $55.89 vs $57.43 consensus PT and a $58.62 52-week high, the easy re-rating R/R is gone. A fresh entry here buys ~3% to consensus with the near-term binary already resolved.
• Volatility is the engine, and it mean-reverts: Q1 strength was explicitly attributed to elevated volatility in Market Making and Hedging. If OVX/GVZ compress through Q3, take-rates and market-making P&L fade, and the +48% comp becomes a brutal forward hurdle.
• NII is a hidden rate bet: ~$16bn of clearing balances earns interest income, so a Fed cutting cycle compresses that line directly while the market extrapolates current earnings.
• Legacy-holder overhang: Helikon/CVC/BXC-era holders remain a secondary-offering risk; any placement announcement is an immediate gap-down for a name with thin ADV versus mega-cap financials.
• Redomicile is structural, not a re-rating event: the Bermuda move (approved 2026-05-21, implementation H2 2026) simplifies corporate structure and aligns with Nasdaq-style corporate law, but does not cleanly unlock S&P US-index inclusion. Treating it as an index catalyst misreads it.
• Integration risk scales with cadence: five deals in twelve months raises the odds one underperforms; an acquisitive broker re-rates hard from compounder to rollup-risk on the first bad integration or leverage spike.

Setup & Price Structure

• Last ~$55.89 (≈2026-06-04/05), market cap $4.02B, P/E 11.58, dividend yield 1.1%. 52-week range $27.91–$58.62; 90-day return +39.9%; 1-day +5.7% into the print/Levmet news.
• Price sits in the top decile of its annual range with the Q1 binary behind it and no scheduled catalyst inside 30 days extended after the event.
• Consensus PT $57.43 (UBS $60 high). Spot is ~3% under consensus and ~7% under the $60 high target, leaving limited headroom to sell-side anchors absent upward estimate revisions.
• This is a compounder: the trim/exit filter is a weekly close below the rising 20-EMA (validate on tape, roughly the $49–50 zone), not an RSI level. RSI>75 here is confirmation of trend, not a sell.
• Tactical read: the constructive entry is a pullback into the rising 20-EMA or the prior breakout shelf; chasing the 52-week-high tape after the catalyst is poor placement. Strength is fine to hold.

Catalyst Calendar (next 30 days)

• Next M&A bolt-on rolling, no fixed date: the ~one-deal-per-quarter cadence plus freshly deployed notes capital makes another announcement plausible within 30–60 days of 2026-06-01; headline-driven, not scheduled.
• Redomiciliation to Bermuda implementation H2 2026 (no fixed date yet): approved at the 2026-05-21 AGM and court meeting; 1-for-1 share swap, continues on Nasdaq as MRX.
• 10% buyback authority (approved 2026-05-21): watch for actual repurchase disclosure as a demand signal.
• Q2 2026 earnings ~2026-08-06 (est.): the next hard binary and the real test of whether the volatility comp can be lapped; outside the 30-day window.
• No dated catalyst inside the next 30 days the tape between now and the August print is driven by commodity-vol regime and M&A headlines.

What Would Change Our Mind

• Weekly close below the rising 20-EMA (≈$49–50 zone, validate on tape) trend break for a compounder, exit signal.
• A legacy-holder (Helikon/CVC/BXC) secondary-offering announcement gap-exit, do not sit through supply.
• Q2 print (~early August) showing organic growth decelerating below ~+15% YoY or margin rolling under ~20% breaks the compounder frame.
• Sustained OVX/GVZ compression below pre-2026 ranges removes the market-making engine that drove the +48% quarter.
• An integration stumble or leverage spike from the next bolt-on that re-rates the multiple from compounder toward rollup-risk.

Correlation Notes

• Revenue is structurally long commodity volatility: OVX (energy vol) and GVZ (gold vol) are the cleanest read-throughs; sustained low realized vol is the core headwind.
• Volume-correlated to LME/CME/ICE cleared activity; rising exchange ADV is a tailwind to clearing and execution fees.
• Peer/comp set: StoneX (SNEX) as the closest diversified-FCM comparable; Virtu (VIRT) and Interactive Brokers (IBKR) for the market-making and electronic-execution read; TP ICAP / BGC for the interdealer-broker comp.
• Hidden rate sensitivity: net interest income on ~$16bn client/clearing balances rises with policy rates and compresses on cuts the stock carries a short-duration rate-beneficiary element.
• Low correlation to the mega-cap tech/AI factor; behaves as a commodity-cycle plus capital-markets-activity beta, useful as a diversifier against an AI-narrative-heavy book.